15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Seres Therapeutics Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $12.00 to $22.00, a moderate spread. The average target of $17.00 sits 254% above the current $4.80. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.64 next quarter toward $-6.58 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Seres Therapeutics Inc.
As of Jul, 2 of 2 firms rate MCRB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MCRB EPS & revenue forecast
EPS · NEXT QUARTER
$-1.64
Range $-2.37 – $-0.90 · 2 analysts · -274% YoY
Next period, 2 analysts expect Seres Therapeutics Inc to earn $-1.64 a share (range $-2.37 – $-0.90), versus $0.94 a year earlier. Full-year consensus is $-7.51, growing to $-6.58 the year after.
REVENUE · NEXT QUARTER
$6.3M
Range $0 – $12.5M · 2 analysts · +1681% YoY
Revenue is expected to reach $6.3M (range $0 – $12.5M), +1680.6% year-over-year. Full-year consensus is $12.9M, rising to $358.0K next year.
Top analysts covering Seres Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MCRB.
#1
Keay Nakae
Chardan Capital · Rank #130
Hold
$6.00+25.0% to target
Overall win rate
41%
+ Follow
#2
Edward Tenthoff
Piper Sandler · Rank #277
Hold
$20.00+316.7% to target
Overall win rate
29%
+ Follow
#3
John Newman
Canaccord Genuity · Rank #340
Buy
$22.00+358.3% to target
Overall win rate
30%
+ Follow
#4
MK
Matthew Keller
HC Wainwright & Co.
Buy
$12.00+150.0% to target
Coverage
—
+ Follow
#5
Joseph Thome
TD Cowen
Buy
No targeton MCRB
Coverage
—
+ Follow
MCRB stock forecast FAQ
What is MCRB's average 12-month price target?+
The 2 analysts with a live target average $17.00 for Seres Therapeutics Inc over the next 12 months, ranging from a $22.00 high to a $12.00 low.
Is MCRB stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MCRB?+
The Street-high target is $22.00 (Canaccord Genuity), and the Street-low is $12.00 (HC Wainwright & Co.). The average of all 2 active targets is $17.00.
How many Wall Street analysts cover MCRB?+
2 analysts have an active rating on Seres Therapeutics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering MCRB?+
Among analysts who currently cover MCRB, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Hold with a $6.00 target.
What is Seres Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.64 per share (range $-2.37 – $-0.90) across 2 analysts. Full-year EPS is projected at $-7.51, rising to $-6.58 the following year.
How much revenue is Seres Therapeutics Inc expected to report next quarter?+
Consensus revenue is $6.3M (range $0 – $12.5M). Full-year revenue is projected at $12.9M, growing to $358.0K next year.
Have analysts been upgrading or downgrading MCRB lately?+
As of Jul, 2 of 2 firms rate MCRB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MCRB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
